Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms

What is it about?

Dyslipidemia is a major risk factor for cardiovascular diseases in diabetic patients and is characterized by a global imbalance of the plasma lipid profile. So far, therapies aiming at reducing total cholesterol and/or triglycerides levels are failing in reducing the cardiovascular risk. Many of these pharmaceutical approaches are directed against one specific target. Here, we propose a novel approach where we are able to regulates 2 biological targets with 1 single compound which would limit the unwanted drug-drug interaction often encountered when combining drugs. In obese mice, we found this approach to be of superior benefit as we were able to strongly improve these animals’ health by regulating different aspects of the lipid metabolism.

Featured Image